전장 엑솜 시퀀싱 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Whole Exome Sequencing Market size is expected to reach USD 8.05 Billion in 2034 from USD 2.21 Billion (2025) growing at a CAGR of 15.47% during 2026-2034.

The global whole exome sequencing market has grown rapidly due to advancements in genomic research and increasing interest in personalized medicine. Whole exome sequencing focuses on analyzing the protein-coding regions of genes, which are responsible for many genetic diseases. The technology has become an important tool in medical research, diagnostics, and drug discovery, supporting the market's steady expansion.

Key drivers include the rising prevalence of genetic disorders and increasing demand for precise diagnostic methods. Researchers and healthcare providers are using whole exome sequencing to identify disease-causing mutations and develop targeted therapies. Additionally, declining sequencing costs and improvements in bioinformatics tools have made the technology more accessible for research institutions and clinical laboratories.

The future outlook for the whole exome sequencing market remains promising as genomic medicine continues to advance. Growing adoption in clinical diagnostics, cancer research, and rare disease studies may expand its applications further. Integration with artificial intelligence and large genomic databases could enhance data interpretation. As precision medicine becomes more widely adopted, whole exome sequencing is expected to play a critical role in healthcare innovation.

MARKET SEGMENTATION

By Product Type

• Instruments
• Consumables
• Services
• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Other Technologies

By Application

• Drug Discovery & Development
• Clinical Diagnostics
• Research

By Indication

• Cancer
• Rare/Inherited Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Others

By End User

• Hospitals & Clinics
• Diagnostics Laboratories
• Academic and Research Institutes
• Biopharmaceutical Companies

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Roche Diagnostics F Hoffmann La Roche Ltd, Illumina Inc, Eurofins Scientific SE, QIAGEN NV, BGI Genomics Co Ltd, Novogene Co Ltd, Pacific Biosciences of California Inc, Agilent Technologies Inc, Genomatix GmbH, Myriad Genetics Inc, Bio Rad Laboratories Inc, Laboratory Corporation of America Holdings, Oxford Nanopore Technologies plc, Novogene Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY SEQUENCING BY SYNTHESIS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Sequencing By Synthesis
• 5.2. Ion Semiconductor Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Other Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY INDICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Indication
• 7.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Rare/Inherited Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Diagnostics Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product Type
  • 9.2.2 By Sequencing By Synthesis
  • 9.2.3 By Application
  • 9.2.4 By Indication
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product Type
  • 9.3.2 By Sequencing By Synthesis
  • 9.3.3 By Application
  • 9.3.4 By Indication
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product Type
  • 9.4.2 By Sequencing By Synthesis
  • 9.4.3 By Application
  • 9.4.4 By Indication
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product Type
  • 9.5.2 By Sequencing By Synthesis
  • 9.5.3 By Application
  • 9.5.4 By Indication
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product Type
  • 9.6.2 By Sequencing By Synthesis
  • 9.6.3 By Application
  • 9.6.4 By Indication
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL WHOLE EXOME SEQUENCING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Thermo Fisher Scientific Inc
  • 11.2.2 Roche Diagnostics (F. Hoffmann La Roche Ltd.)
  • 11.2.3 Illumina Inc
  • 11.2.4 Eurofins Scientific SE
  • 11.2.5 QIAGEN N.V
  • 11.2.6 BGI Genomics Co. Ltd
  • 11.2.7 Novogene Co. Ltd
  • 11.2.8 Pacific Biosciences Of California Inc
  • 11.2.9 Agilent Technologies Inc
  • 11.2.10 Genomatix GmbH
  • 11.2.11 Myriad Genetics Inc
  • 11.2.12 Bio Rad Laboratories Inc
  • 11.2.13 Laboratory Corporation Of America Holdings
  • 11.2.14 Oxford Nanopore Technologies Plc
  • 11.2.15 Novogene Co. Ltd